PerkinElmer newborn screening test gets CE Mark

By LabPulse.com staff writers

September 30, 2020 -- PerkinElmer has received the CE Mark for its reverse transcription polymerase chain reaction (RT-PCR) newborn screening assay.

The company's Eonis test screens for spinal muscular atrophy, severe combined immunodeficiency, and X-linked agammaglobulinemia in newborns and will be integrated into PerkinElmer's sample-to-result workflow.

PerkinElmer debuts dried blood spot-based COVID-19 serology test
PerkinElmer has introduced a dry blood spot-based serology test for SARS-CoV-2 immunoglobulin G antibodies using its genetic screening processor/dissociation-enhanced...
PerkinElmer predicts 12% growth in Q2
PerkinElmer has announced an updated outlook for the second quarter of 2020, predicting 12% revenue growth.
PerkinElmer says it's not target of federal probe
PerkinElmer on May 18 said that while the company had received subpoenas from federal investigators looking into healthcare fraud at medical labs, the...
FDA-authorized antibody tests fall short in comparative study
Commercial serology tests from PerkinElmer subsidiary Euroimmun and Abbott fell short of expectations in a comparative study of specimens, underscoring...
PerkinElmer Q1 revenues edge up, profit edges down
In financial results for the first quarter, PerkinElmer saw revenues grow slightly, but net income slipped.

Copyright © 2020 LabPulse.com

Last Updated ls 9/30/2020 2:45:32 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email